I typically write on small cap and other stocks which are much less followed than Tesla (TSLA) because doing so helps fill an obvious coverage void. TSLA, on the other hand, is extremely well-covered, and so there's less of an opportunity to make new points and/or present a fresh angle. Indeed, I regularly read all of the short-side experts (Montana Skeptic, EnerTuition, Anton Wahlman, etc.) as well as many of the best longs to get a better understanding of the opposite side of my trade (Trent Eady, ValueAnalyst, Randy Carlson, etc.) Yet while the coverage from both sides is extensive and extremely thought provoking, the sheer volume and pursuit of minor details can often obscure the essential investment (short) case. For example, while it's very interesting to ferret out the costs of each supercharger location, in the end, the results won't materially affect the probabilities of TSLA's ultimate success or failure.
In order to stay focused on the bigger picture, I like to review my longer term positions every six months or so, with the goal of distilling my investment case, including identifying any potential developments which might cause me to change my mind. In this article, I present the results of my review in the form of a top 5 list of reasons (in order of importance) for why I have a long-term TSLA short position, in the hopes that it might also be helpful to other readers who may have become overwhelmed with the volume of TSLA coverage.
Top 5 Small Cap Stocks To Own For 2019: ATA Inc.(ATAI)
Advisors' Opinion:- [By Paul Ausick]
ATA Inc. (NASDAQ: ATAI) traded down about 14% Monday to set a new 52-week low of $0.82, based on revalued shares that closed at $0.72 on Friday but traded up about 250% on Monday at $2.53. Volume was more than 200 times the daily average of around 42,000. You’re on your own here to figure this one out.
Top 5 Small Cap Stocks To Own For 2019: FuelCell Energy Inc.(FCEL)
Advisors' Opinion:- [By Ethan Ryder]
FuelCell Energy (NASDAQ: FCEL) and Integer (NYSE:ITGR) are both oils/energy companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.
- [By Shane Hupp]
FuelCell Energy (NASDAQ: FCEL) is one of 25 public companies in the “Miscellaneous electrical machinery, equipment, & supplies” industry, but how does it contrast to its peers? We will compare FuelCell Energy to related companies based on the strength of its risk, dividends, earnings, valuation, profitability, analyst recommendations and institutional ownership.
- [By Paul Ausick]
FuelCell Energy Inc. (NASDAQ: FCEL) posted a dip of 0.5% in short interest during the two weeks. Some 9.88 million shares were short as of August 31. The stock closed at $1.08 on Wednesday, up about 1.9% for the day, in a 52-week range of $1.00 to $2.49. Shares traded up about 14.4% in the two-week short interest period, and days to cover rose from nine to 12.
Top 5 Small Cap Stocks To Own For 2019: Petroquest Energy Inc(PQ)
Advisors' Opinion:- [By Ethan Ryder]
News headlines about Petroquest Energy (NYSE:PQ) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Petroquest Energy earned a coverage optimism score of 0.05 on Accern’s scale. Accern also gave news stories about the energy company an impact score of 47.638327846877 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Top 5 Small Cap Stocks To Own For 2019: China Metro-Rural Holdings Limited(CNR)
Advisors' Opinion:- [By Shane Hupp]
Wall Street analysts expect that Canadian National Railway (NYSE:CNI) (TSE:CNR) will announce $1.02 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Canadian National Railway’s earnings, with the highest EPS estimate coming in at $1.06 and the lowest estimate coming in at $0.97. Canadian National Railway reported earnings per share of $1.00 in the same quarter last year, which would suggest a positive year over year growth rate of 2%. The company is expected to announce its next quarterly earnings results on Tuesday, July 24th.
- [By Ethan Ryder]
State of Tennessee Treasury Department lessened its stake in shares of Canadian National Railway (NYSE:CNI) (TSE:CNR) by 1.6% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 842,775 shares of the transportation company’s stock after selling 13,507 shares during the quarter. State of Tennessee Treasury Department owned about 0.11% of Canadian National Railway worth $61,565,000 as of its most recent filing with the SEC.
- [By Shane Hupp]
Canadian National Railway (TSE:CNR) (NYSE:CNI) had its target price upped by investment analysts at CIBC from C$116.00 to C$120.00 in a research report issued on Friday. CIBC’s price objective suggests a potential upside of 3.54% from the stock’s current price.
Top 5 Small Cap Stocks To Own For 2019: Achillion Pharmaceuticals Inc.(ACHN)
Advisors' Opinion:- [By Shane Hupp]
News articles about Achillion Pharmaceuticals (NASDAQ:ACHN) have trended somewhat positive this week, Accern Sentiment reports. The research firm ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Achillion Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.941587509483 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
- [By Lisa Levin] Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) rose 29.4 percent to $5.50 in pre-market trading after the company disclosed that its first pivotal Phase 3 trial of IV tramadol achieved the primary and key secondary endpoints. MB Financial, Inc. (NASDAQ: MBFI) rose 16.8 percent to $51.00 in pre-market trading. Fifth Third Bancorp (NASDAQ: FITB) agreed to acquire MB Financial for $54.70 per share in cash and stock. LiveXLive Media, Inc. (NASDAQ: LIVX) rose 9.3 percent to $5.40 in pre-market trading after falling 28.92 percent on Friday. Celyad SA (NASDAQ: CYAD) shares rose 9 percent to $29.30 in pre-market trading after climbing 3.26 percent on Friday. Ethan Allen Interiors Inc. (NYSE: ETH) rose 6.7 percent to $26.40 in pre-market trading after gaining 1.64 percent on Friday. Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) rose 5.4 percent to $3.90 in pre-market trading after gaining 3.06 percent on Friday. Acacia Communications, Inc. (NASDAQ: ACIA) rose 5.2 percent to $34.70 in pre-market trading after gaining 1.38 percent on Friday. Westinghouse Air Brake Technologies Corporation (NYSE: WAB) rose 5.1 percent to $100 in pre-market trading. General Electric Company (NYSE: GE) agreed to merge its transportation unit with Wabtec. Sunrun Inc. (NASDAQ: RUN) shares rose 4.7 percent to $11.50 in pre-market trading. Nasdaq, Inc. (NASDAQ: NDAQ) shares rose 4.3 percent to $93.98 in the pre-market trading session. LaSalle Hotel Properties (NYSE: LHO) shares rose 4.2 percent to $33.25 in pre-market trading. Blackstone Group LP (NYSE: BX) will buy LaSalle Hotel Properties in a $4.8 billion deal, Bloomberg reported. Monro, Inc. (NASDAQ: MNRO) shares rose 4 percent to $58.35 in pre-market trading as the company posted upbeat quarterly earnings and disclosed that it has acquired Free Service Tire. HUYA Inc. (NYSE: HUYA) rose 3.7 percent to $19.75 in pre-market trading after falling 4.80 percent on Friday.
Find out what's going
- [By Logan Wallace]
Get a free copy of the Zacks research report on Achillion Pharmaceuticals (ACHN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Ethan Ryder]
Achillion Pharmaceuticals (NASDAQ:ACHN) – Research analysts at B. Riley reduced their FY2018 EPS estimates for shares of Achillion Pharmaceuticals in a research note issued to investors on Wednesday, May 2nd. B. Riley analyst M. Kumar now anticipates that the biopharmaceutical company will earn ($0.58) per share for the year, down from their previous estimate of ($0.55). B. Riley has a “Neutral” rating and a $3.50 price objective on the stock. B. Riley also issued estimates for Achillion Pharmaceuticals’ FY2019 earnings at ($0.64) EPS, FY2020 earnings at ($0.71) EPS, FY2021 earnings at ($0.70) EPS and FY2022 earnings at ($0.84) EPS.
- [By Keith Speights]
Skeptics might deride a comparison of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) as an exercise in finding the biggest loser. Both companies continue to post huge net losses every quarter, and their stocks are down by at least 30% over the last 12 months.
- [By Stephan Byrd]
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shares saw strong trading volume on Friday . 40,274 shares changed hands during trading, a decline of 96% from the previous session’s volume of 999,221 shares.The stock last traded at $2.62 and had previously closed at $2.72.
No comments:
Post a Comment